Locations:

Tag: nonvalvular atrial fibrillation

Boston Scientific Corporation WATCHMAN FLX Device

March 15, 2023/Heart, Vascular and Thoracic/Electrophysiology

Watchman FLX at 1 Year: Real-World Performance Consistent With Trial Results

Large SURPASS registry study confirms high seal rates, acceptable safety

March 16, 2022/Heart, Vascular and Thoracic/Electrophysiology

SURPASS Study Confirms Real-World Safety and Efficacy of Watchman FLX Through 45 Days

Interim report from large registry analysis compares favorably with pivotal trial

November 9, 2021/Heart, Vascular and Thoracic/Electrophysiology

Insights From 1,000+ Left Atrial Appendage Closure Procedures With Watchman

Even very high-risk patients benefit, and implantation can safely be combined with ablation or TAVR

February 6, 2019/Heart, Vascular and Thoracic/Advancing Patient Care

Left Atrial Appendage Closure Device Found Safe and Effective for AF Despite Prior ICH

Study supports new stroke prevention option for high-risk group

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

May 11, 2018/Heart, Vascular and Thoracic/Research

Watchman in the Real World: Reports on Use in High-Risk Patients and Overall Safety

Recaps of three studies from Cleveland Clinic’s experience to date

June 18, 2015/Heart, Vascular and Thoracic/News & Insights

LAA Closure Device a Reality: Now What? (Video)

An expert’s take on FDA’s ‘appropriate rationale’ caveat

BackPage 1 of 1Next